Commerce Bank bought a new stake in shares of Cambrex Co. (NYSE:CBM) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,340 shares of the biotechnology company’s stock, valued at approximately $294,000.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Boston Partners purchased a new stake in Cambrex in the 3rd quarter worth about $17,869,000. Marshall Wace North America L.P. raised its position in Cambrex by 2,239.4% in the 2nd quarter. Marshall Wace North America L.P. now owns 266,106 shares of the biotechnology company’s stock worth $15,966,000 after purchasing an additional 254,731 shares during the period. FMR LLC raised its position in Cambrex by 19.1% in the 2nd quarter. FMR LLC now owns 1,070,645 shares of the biotechnology company’s stock worth $63,971,000 after purchasing an additional 171,559 shares during the period. Congress Asset Management Co. MA raised its position in Cambrex by 8.7% in the 2nd quarter. Congress Asset Management Co. MA now owns 1,297,023 shares of the biotechnology company’s stock worth $77,497,000 after purchasing an additional 103,900 shares during the period. Finally, OxFORD Asset Management LLP purchased a new stake in Cambrex in the 2nd quarter worth about $4,670,000.
A number of research firms recently weighed in on CBM. BidaskClub lowered shares of Cambrex from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. ValuEngine lowered shares of Cambrex from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Craig Hallum reaffirmed a “buy” rating and set a $60.00 target price (down from $70.00) on shares of Cambrex in a research report on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Cambrex presently has a consensus rating of “Hold” and an average price target of $62.33.
In other news, CEO Steven M. Klosk sold 4,000 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $54.96, for a total transaction of $219,840.00. Following the transaction, the chief executive officer now directly owns 87,328 shares in the company, valued at $4,799,546.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.48% of the stock is currently owned by company insiders.
Shares of Cambrex Co. (NYSE:CBM) traded up $0.15 during trading hours on Thursday, hitting $49.15. 359,721 shares of the stock were exchanged, compared to its average volume of 337,702. The stock has a market capitalization of $1,602.82, a price-to-earnings ratio of 15.43, a PEG ratio of 1.10 and a beta of 2.26. Cambrex Co. has a fifty-two week low of $42.55 and a fifty-two week high of $62.95.
Cambrex (NYSE:CBM) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.08. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The firm had revenue of $112.60 million for the quarter, compared to the consensus estimate of $108.44 million. During the same period last year, the firm earned $0.47 earnings per share. The company’s quarterly revenue was up 13.4% on a year-over-year basis. equities research analysts forecast that Cambrex Co. will post 2.97 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2017/12/07/5340-shares-in-cambrex-corporation-cbm-purchased-by-commerce-bank-updated-updated.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Co. and related companies with MarketBeat.com's FREE daily email newsletter.